Business model

PharmaLundensis develops effective treatments for  various lung diseases.

The pharmaceutical drugs are tested and optimized in clinical studies, and then sold directly on the market or outlicensed to other pharmaceutical companies on local markets.

In addition, the company develops an effective system to remove pharmaceutical drugs and multi-resistant bacteria in hospital sewage water (EcoFilter).

Central for our strategy is a strong patent portfolio.

Business goals, 1 year
Performed a successful COPD clinical study.
Treatment for chronic bronchitis “Bronkitstopp” on the market.
Tentative results in Flu-treatment project.
Clinical testing of EcoFilter system in 1-2 hospitals.

Business goals, 3 years
Registered Iodocarb for sale in Europe.
Positive results confirmed in Flu-treatment project. Outlicensed projekt to major pharma-company.
Completed clinical testing of EcoFilter system in Swedish hospitals. A business model where hospitals subscribe to the EcoFilter system on 5-10 year contracts is planned. The hospitals will pay a monthly subscription fee to cover the running costs of the EcoFilter system.

Business goals, 5 years
Registered Iodocarb for sale on most markets in the world. Outlicensed Iodocarb to at least 3 medium-sized local pharma companies. Annual sale of Iodocarb >100 MEUR.
License fee from Flu-treatment project >20 MEUR/year.
Annual revenues from direct sales and licensing in EcoFilter project: 17 MEUR.

Business goals, 10 years
Iodocarb sales >1 billion EUR/year.
License fee from Flu-treatment project >100 MEUR/year.
Annual revenues from direct sales and licensing in EcoFilter project: 90 MEUR.